Latest filing published 14 Oct 2021 for Cognition Therapeutics INC, €52k.
Filing timeline
BuySaleInsider track record
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
No signal scores available.
James Michael O'Brien: trading record in brief
James Michael O'Brien (finance chief) discloses dealings in 2 companies, chiefly Enzo Biochem Inc and Cognition Therapeutics Inc. Between 13 June 2017 and 13 October 2021, the trades on record add up to 9 filings.
Market trades split into 1 purchase (€52k) and 5 sales (€345k). Sales outweigh purchases by €293k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 3 option exercises. 2021 to date brings 1 purchase and no sales.
Most recently, on 14 October 2021, the filings show an open-market purchase worth €52k in Cognition Therapeutics Inc. Typically, a trade is published a median of 3 days after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to James Michael O'Brien
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,000 shares@ US$12.00100.0% of flowCommon StockSEC:0001104659-21-126361:0Canonical exit: 11 Jan 2022 (T+90)
1 of 1 declaration
